Skip to main content

Diabinese Side Effects

Generic name: chlorpropamide

Medically reviewed by Last updated on Feb 7, 2023.

Note: This document contains side effect information about chlorpropamide. Some dosage forms listed on this page may not apply to the brand name Diabinese.

Applies to chlorpropamide: oral tablet.

Serious side effects of Diabinese

Along with its needed effects, chlorpropamide (the active ingredient contained in Diabinese) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor immediately if any of the following side effects occur while taking chlorpropamide:


Incidence not known

Other side effects of Diabinese

Some side effects of chlorpropamide may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More common

Less common


Incidence not known

For Healthcare Professionals

Applies to chlorpropamide: oral tablet.


The most commonly reported adverse reactions have included gastrointestinal disturbances such as nausea, diarrhea, vomiting, anorexia, and hunger.[Ref]


Rare (less than 0.1%): Disulfiram-like reactions

Frequency not reported: Hypoglycemia


Frequency not reported: Hepatic porphyria[Ref]


Common (1% to 10%): Nausea, diarrhea, vomiting, anorexia, hunger

Frequency not reported: Proctocolitis[Ref]


Uncommon (0.1% to 1%): Pruritus, allergic skin reactions (pruritus, erythema, urticaria, and morbilliform or maculopapular eruptions)


Frequency not reported: Photosensitivity, porphyria cutanea tarda[Ref]


Frequency not reported: Allergic skin reactions


Rare (less than 0.1%): Cholestatic jaundice, hepatitis

Frequency not reported: Hepatic porphyria[Ref]



Frequency not reported: Leukopenia, agranulocytosis, thrombocytopenia, hemolytic anemia, aplastic anemia, pancytopenia, eosinophilia[Ref]



Frequency not reported: Increased cardiovascular mortality[Ref]

In the University Group Diabetes Program (UGDP) study, cardiovascular mortality rate was approximately 2.5 times higher in patients treated for 5 to 8 years with diet plus tolbutamide 1.5 g per day compared with that of patients treated with diet alone. The UGDP study was a long-term prospective clinical trial designed to evaluate the effectiveness of glucose lowering drugs in preventing or delaying vascular complications in patients with type 2 diabetes mellitus (n=823). Tolbutamide was stopped based on the increase in cardiovascular mortality; a significant increase in total mortality was not observed, but stopping the drug may have limited the ability to measure that. In view of the close similarities in mode of action and chemical structure among sulfonylureas, these results may apply to other drug in this class.[Ref]

Nervous system

Frequency not reported: Dizziness, headache[Ref]


1. Product Information. Diabinese (chlorpropamide). Pfizer U.S. Pharmaceuticals. 2002;PROD.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.